Texas Public Radio

Texans can screen for cervical cancer with first FDA-approved, at-home pap smear alternative

The FDA approved the first at-home cervical cancer screening in May. Texas is the eighth state to have access to the test as ...

Johnson & Johnson: Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength ...
The Malaysian Reserve

Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the ...